相似文献
1
Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.AR、ESR1 和 ESR2 基因的遗传变异与前列腺癌侵袭性或雄激素剥夺治疗的疗效无关。
Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1871-8. doi: 10.1158/1055-9965.EPI-10-0216.
2
Association between estrogen and androgen receptor genes and prostate cancer risk.雌激素和雄激素受体基因与前列腺癌风险之间的关联。
Eur J Endocrinol. 2009 Jan;160(1):101-6. doi: 10.1530/EJE-08-0321. Epub 2008 Oct 24.
3
Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer.雌激素受体 α 和 β 的遗传多态性与前列腺癌发病风险的关系。
PLoS One. 2009 Aug 5;4(8):e6523. doi: 10.1371/journal.pone.0006523.
4
Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women.雌激素受体 (ESR1、ESR2) 和雄激素受体 (AR) 基因中的微卫星与非裔美国人和尼日利亚女性的乳腺癌风险。
PLoS One. 2012;7(7):e40494. doi: 10.1371/journal.pone.0040494. Epub 2012 Jul 11.
5
Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.甾体激素受体超家族基因多态性改变与绝经后激素治疗相关的绝经后乳腺癌风险。
Int J Cancer. 2010 Jun 15;126(12):2935-46. doi: 10.1002/ijc.24892.
6
Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms.前列腺癌风险与雌激素受体1（ESR1）TA、雌激素受体2（ESR2）CA重复序列多态性
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2233-6. doi: 10.1158/1055-9965.EPI-07-0481.
7
Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer.雌激素受体α、β（ESR1、ESR2）和雄激素受体（AR）基因中的重复多态性与乳腺癌发生的关联。
Breast. 2008 Apr;17(2):159-66. doi: 10.1016/j.breast.2007.08.007. Epub 2007 Sep 29.
8
Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.美国国立癌症研究所乳腺癌与前列腺癌队列联盟中雌激素受体β的序列变异与前列腺癌风险
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1973-81. doi: 10.1158/1055-9965.EPI-07-0431.
9
The influence of microsatellite polymorphisms in sex steroid receptor genes ESR1, ESR2 and AR on sex differences in brain structure.雌激素受体基因 ESR1、ESR2 和 AR 中的微卫星多态性对大脑结构性别差异的影响。
Neuroimage. 2020 Nov 1;221:117087. doi: 10.1016/j.neuroimage.2020.117087. Epub 2020 Jun 25.
10
The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk.ESR1基因rs9340799和ESR2基因rs1256049多态性对前列腺癌风险的影响。
Tumour Biol. 2014 Aug;35(8):8319-28. doi: 10.1007/s13277-014-2086-7. Epub 2014 May 24.
引用本文的文献
1
Association between estrogen receptor β polymorphisms and prostate cancer in a Slovak population.斯洛伐克人群中雌激素受体β基因多态性与前列腺癌的关联。
Oncol Lett. 2021 Mar;21(3):214. doi: 10.3892/ol.2021.12475. Epub 2021 Jan 19.
2
Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.前列腺癌患者中PTEN、AKT1、PI3K、AR和AMACR基因多态性的关联
Genet Mol Biol. 2020 Jun 1;43(3):e20180329. doi: 10.1590/1678-4685-GMB-2018-0329.
3
Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.前列腺癌的种系基因谱分析：最新进展与潜在临床应用
Future Sci OA. 2015 Dec 18;2(1):FSO87. doi: 10.4155/fso.15.87. eCollection 2016 Mar.
4
The genetic epidemiology of prostate cancer and its clinical implications.前列腺癌的遗传流行病学及其临床意义。
Nat Rev Urol. 2014 Jan;11(1):18-31. doi: 10.1038/nrurol.2013.266. Epub 2013 Dec 3.
5
ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis.ESR1基因多态性与前列腺癌风险：一项HuGE综述与荟萃分析
PLoS One. 2013 Jun 21;8(6):e66999. doi: 10.1371/journal.pone.0066999. Print 2013.
6
Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer.基于生物标志物对晚期前列腺癌中雄激素-雄激素受体轴的靶向治疗
Adv Urol. 2012;2012:781459. doi: 10.1155/2012/781459. Epub 2012 Aug 22.
7
Germline predictors of androgen deprivation therapy response in advanced prostate cancer.晚期前列腺癌中雄激素剥夺治疗反应的种系预测因子。
Mayo Clin Proc. 2012 Mar;87(3):240-6. doi: 10.1016/j.mayocp.2011.09.009.
8
The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.常见的性激素代谢途径基因中的遗传变异对甾体激素水平和前列腺癌侵袭性的影响。
Cancer Prev Res (Phila). 2011 Dec;4(12):2044-50. doi: 10.1158/1940-6207.CAPR-11-0283. Epub 2011 Sep 7.
9
Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China.血管紧张素转换酶插入/缺失多态性与中国汉族人群前列腺癌的风险。
Med Oncol. 2012 Sep;29(3):1964-71. doi: 10.1007/s12032-011-0051-5. Epub 2011 Aug 28.
10
Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.趋化因子 CCL2 基因中的遗传变异与白种人群前列腺癌侵袭性的关系。
Clin Cancer Res. 2011 Mar 15;17(6):1546-52. doi: 10.1158/1078-0432.CCR-10-2015. Epub 2010 Dec 6.
本文引用的文献
1
Molecular mechanisms of castration-resistant prostate cancer progression.去势抵抗性前列腺癌进展的分子机制。
Future Oncol. 2009 Nov;5(9):1403-13. doi: 10.2217/fon.09.117.
2
Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer.雌激素受体 α 和 β 的遗传多态性与前列腺癌发病风险的关系。
PLoS One. 2009 Aug 5;4(8):e6523. doi: 10.1371/journal.pone.0006523.
3
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
4
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.8q24和17q风险位点与前列腺癌死亡率的评估
Clin Cancer Res. 2009 May 1;15(9):3223-30. doi: 10.1158/1078-0432.CCR-08-2733. Epub 2009 Apr 14.
5
Amplification and co-regulators of androgen receptor gene in prostate cancer.前列腺癌中雄激素受体基因的扩增及共调节因子
Exp Oncol. 2009 Mar;31(1):3-8.
6
Mortality results from a randomized prostate-cancer screening trial.一项前列腺癌随机筛查试验的死亡率结果。
N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18.
7
The evolving role of oestrogens and their receptors in the development and progression of prostate cancer.雌激素及其受体在前列腺癌发生发展中的演变作用。
Eur Urol. 2009 Mar;55(3):533-42. doi: 10.1016/j.eururo.2008.10.035. Epub 2008 Nov 6.
8
Association between estrogen and androgen receptor genes and prostate cancer risk.雌激素和雄激素受体基因与前列腺癌风险之间的关联。
Eur J Endocrinol. 2009 Jan;160(1):101-6. doi: 10.1530/EJE-08-0321. Epub 2008 Oct 24.
9
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.雄激素剥夺疗法（ADT）在晚期前列腺癌患者中的疗效： Gleason评分、前列腺特异性抗原水平以及既往ADT暴露与ADT疗效持续时间之间的关联。
Cancer. 2008 Mar 15;112(6):1247-53. doi: 10.1002/cncr.23304.
10
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.雄激素途径的遗传变异与前列腺癌男性患者雄激素剥夺治疗的疗效相关。
J Clin Oncol. 2008 Feb 20;26(6):842-7. doi: 10.1200/JCO.2007.13.6804.
Zotero 插件